Browsing by Author "Uzay, Ant"

Now showing 1 - 4 of 4

Does it take three to tango? An unsuspected multimorbidity of CD8(+) T cell lymphoproliferative disorder, malaria, and EBV infection
(BMC, 2018-01-01) Ekemen, Suheyla; Uzay, Ant; Bassullu, Nuray; Dikicioglu-Cetin, Emel; Matsuda, Kyoko; Ince, Umit; Coban, Cevayir
Background: Malaria is known to cause acute and deadly complications. However, malaria can cause unforeseen pathologies due to its chronicity. It increases the risk of endemic Burkitt Lymphoma development by inducing DNA damage in germinal centre (GC) B cells, and leading higher frequency of Epstein-Barr virus (EBV)-infected cells in GCs. EBV is well known for its tropism for B cells. However, less is known about EBV's interaction with T cells and its association with T cell lymphoma. Case presentation: A 43-year-old Sudanese male admitted to hospital in Istanbul, Turkey, a non-endemic country, with hyperpigmented painful skin rashes on his whole body. A complete blood count and a peripheral blood smear during admission revealed large granular lymphocytes (LGLs) with abnormally higher CD8 T cell numbers. Additional skin biopsy and pathology results were compatible with CD8(+) T cell lymphoproliferative disorder with skin involvement. Patient was treated and discharged. However, a pathologist noticed unusual structures in skin tissue samples. Careful evaluation of skin biopsy samples by polarized microscopy revealed birefringent crystalloid structures resembling malarial haemozoin mainly loaded in macrophages and giant histiocytes. After purification of DNA from the skin biopsy samples, nested PCR was performed for the detection of Plasmodium parasites and Plasmodium falciparum DNA was amplified. Because, the co-presence of EBV infection with malaria is a well-known aetiology of lymphoma, EBV-early RNA (EBER) transcripts were investigated in paraffin-embedded tissue samples and found to be positive in macrophage-like histiocytes. Conclusions: This is a unique case of malaria and EBV infection in a T-LGL lymphoma patient who presented in a non-endemic country. This case emphasizes the clinical importance of EBV monitoring in T-LGL patients with skin involvement. Notably, Plasmodium infection should be examined in patients from malaria endemic regions by pathological and molecular investigations.
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
(SPRINGER, 2023-01-01) Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur; Bekoz, Huseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulas, Turgay; Karti, Sami; Altuntas, Fevzi; Ferhanoglu, Burhan; Tuglular, Tulin Firat
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9\%, including 32.4\% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
(MASSACHUSETTS MEDICAL SOC, 2021-01-01) Zeiser, Robert; Polverelli, Nicola; Ram, Ron; Hashmi, Shahrukh K.; Chakraverty, Ronjon; Middeke, Jan Moritz; Musso, Maurizio; Giebel, Sebastian; Uzay, Ant; Langmuir, Peter; Hollaender, Norbert; Gowda, Maanasa; Stefanelli, Tommaso; Lee, Stephanie J.; Teshima, Takanori; Locatelli, Franco; Investigators, REACH3
Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50\% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD. Methods This phase 3 open-label, randomized trial evaluated the efficacy and safety of ruxolitinib at a dose of 10 mg twice daily, as compared with the investigator's choice of therapy from a list of 10 commonly used options considered best available care (control), in patients 12 years of age or older with moderate or severe glucocorticoid-refractory or -dependent chronic GVHD. The primary end point was overall response (complete or partial response) at week 24
Successful Preoperative Treatment with Plasmapheresis of Patients with Hyperthyroidism
(GALENOS YAYINCILIK, 2018-01-01) Bahsi, Seyma; Uzay, Ant; Rustemova, Nigar; Onder, F. Oguz; Celik, Ozlem
Anti-thyroid drugs are used as the first line treatment in the majority of patients with hyperthyroidism, but side effects such as severe hepatotoxicity and agranulocytosis may occur in some rare cases. For patients suffering from such severe side effects and in need of emergent surgical interventions, the removal of circulating thyroid hormones and thyroid antibodies by preoperative plasmapheresis has been reported as an effective adjunct. In this study, we report two patients, one with Graves' disease who underwent a liver transplantation, and the second with a toxic multinodular goiter and acute cholecystitis due to suspected pancreatic cancer.